Originally spun out of the MIT Department of Chemistry in 2013, C2Sense has developed two distinct product platforms that leverage core technological breakthroughs in chemistry and photography united by the innovative application of fluorescence.
In the diagnostic space, C2Sense’s Halo platform , to provide patients and providers alike with laboratory-level accuracy at low-cost and at the point of need. In the supply chain space, C2Sense creating new product assessment techniques with a growing list of applications including product verification and authentication; moisture, oxygen and temperature sensing; and discrete traceability or visible labeling.
C2Sense is doing amazing work applying technological breakthroughs in chemistry, machine vision, and material science, to provide laboratory-level accuracy at low-cost and at the point of need.
Our Story
Our Team
Headquartered in Watertown, Massachusetts, the Halo team features 14 scientists, engineers, and business leaders designing and implementing innovative solutions with the goal of dependable and accessible diagnostics for all people.
Halo® in the News
Harnessing the unmatched specificity of padlock probe chemistry in combination with isothermal amplification and an optical readout, Helios™ can simultaneously detect hundreds to thousands of targets at single-copy sensitivity levels.
In the newest episode of Innovators & Insights by Drummond Scientific Company, it’s President & CEO Christopher Strohsahl sat down with Joe Walish, Chief Product Officer of Hyperion Biosystems, to discuss why sensitivity is critical in diagnostics—and how Hyperion’s technology is lowering detection limits without increasing false positives. Click here for the full interview.
Hyperion Biosystems and Colorcon today announced a licensing agreement to commercialize and market a jointly-developed, anti-counterfeiting technology for solid oral dosage pharmaceutical and nutraceutical products.
C2Sense, Inc. announces Dr. Michael Mina, MD, Ph.D., joins its Board of Directors as an independent director effective May 24, 2024.
C2Sense, Inc. and Princeton BioMeditech announced they secured a second NIH award.
C2Sense, Inc. has published a paper demonstrating that smartphone-based luminescence imaging can be a promising tool for time-gated measurements.
The funds will be used to accelerate commercialization of a version of PBM’s Status™ COVID-19/Flu A&B antigen test used in conjunction with C2Sense’s Halo diagnostic reader.
C2Sense, Inc., today announced that its Board of Directors has appointed Jim Mahoney, MBA, MMA as an independent director effective January 31, 2023.
C2Sense, Inc., announced Adam Behrens, Ph.D., joins its Board of Directors as an independent director effective January 31, 2023.
C2Sense, Inc., today announced the appointment of the Honorable Andrew Weber to its Board of Directors effective January 31, 2023.
Digital innovation and connected diagnostics can help address global health issues but health governance must advance with new tech.
C2Sense, Inc. announced the successful closing of its $8M Series B financing round with participation from new and existing investors.
C2Sense, Inc., is a technology company developing a suite of diagnostic products for healthcare, wellness and safety.
C2Sense, Inc. published a proof-of-concept study in Frontiers in Public Health demonstrating the sensitivity and specificity of its Halo technology platform to detect SARS-CoV-2.
